MSD is continuing with its clinical development programme in lung cancer. Credit: Soloviova Liudmyla / Shutterstock.

MSD (Merck & Co) has discontinued the Phase III KeyVibe-008 trial designed to evaluate a fixed-dose combination of vibostolimab and pembrolizumab with chemotherapy for extensive-stage small cell lung cancer (ES-SCLC).

The company’s decision follows a recommendation from an independent Data Monitoring Committee (DMC) after a pre-planned analysis indicated that the trial’s primary endpoint of overall survival (OS) met pre-specified futility criteria.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Vibostolimab is an investigational anti-TIGIT antibody developed to activate T lymphocytes and help destroy tumour cells.

The randomised, double-blind Phase III trial aimed to assess the co-formulation of vibostolimab and MSD’s anti-PD-1 therapy pembrolizumab (Keytruda), along with chemotherapy against atezolizumab in combination with chemotherapy, for the first-line treatment of ES-SCLC patients.

It enrolled 460 patients and the secondary endpoints focused on progression-free survival and objective response rate.

See Also:

Patients in the fixed-dose combination arm experienced a higher rate of adverse events (AEs) and immune-related AEs than those in the control arm.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

MSD is now conducting a comprehensive analysis of the study.

Investigators have been informed that patients should cease treatment with the fixed-dose combination and may opt for atezolizumab treatment instead.

MSD, however, is continuing with its clinical development programme in lung cancer, focusing on earlier stages of the disease and new combinations.

Other ongoing Phase III studies of the vibostolimab and pembrolizumab combination in lung cancer are KeyVibe-003, KeyVibe-006 and KeyVibe-007.

Last week, MSD and Daiichi Sankyo dosed the first subject in the Phase III IDeate-Lung02 clinical trial of ifinatamab deruxtecan (I-DXd) in people with relapsed small cell lung cancer (SCLC).